0001493152-22-004469 | 10-K | XBRL Viewer

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Oct. 31, 2021

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE

	As of October 31,
	2021		2020
Warrants		30,225,397		398,226
Stock options		893,946		1,011,768
Restricted stock units		-		5,556
Total		31,119,343		1,415,550

INCOME TAXES

12 Months Ended

Oct. 31, 2021

Income Tax Disclosure [Abstract]

INCOME TAXES

12. INCOME TAXES

The income tax provision (benefit) consists of the following (in thousands):

	October 31, 2021			October 31, 2020
Federal
Current	$	-		$	-
Deferred		141			(4,578	)
State and Local
Current		-			-
Deferred		131			(1,445	)
Foreign
Current		50			50
Deferred		-			-
Change in valuation allowance		(272	)		(6,023	)
Income tax provision (benefit)	$	50		$	50

The Company has U.S. federal net operating loss carryovers (“NOLs”) of approximately $314.8 million and $299.2 million at October 31, 2021 and 2020, respectively, available to offset taxable income. The Company has $56.0 million of NOLs which do not expire, the remainder of which are subject to expiration through 2038. The Company conducted an Internal Revenue Code Section 382 analysis through October 31, 2019. Based on that analysis, some NOLs incurred through October 31, 2019 are subject to limitation and will expire. Subsequent period NOLs have not been studied for the Internal Revenue Code Section 382 limitation. The Company also has New Jersey State Net Operating Loss carryovers of approximately $153.7 million and $137.6 million as of October 31, 2021 and 2020, respectively, available to offset future taxable income through 2041. Utilization of New Jersey NOLs may be similarly limited.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon future generation for taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance.

The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.

If applicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as other expense in the consolidated statement of operations. Penalties would be recognized as a component of general and administrative expenses in the consolidated statement of operations.

No interest or penalties on unpaid tax were recorded during the years ended October 31, 2021 and 2020, respectively. As of October 31, 2021, and 2020, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.

The Company files tax returns in the U.S. federal and state jurisdictions and is subject to examination by tax authorities beginning with the fiscal year ended October 31, 2018.

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands):


	Years Ended
	October 31, 2021			October 31, 2020
Deferred Tax Assets
Net operating loss carryovers	$	32,971		$	28,553
Stock-based compensation		4,566			10,132
Research and development credits		11,371			10,742
Capitalized R&D costs		14,536			13,822
Adoption of ASC 842 – Lease Liability		11			1,691
Other deferred tax assets		92			224
Total deferred tax assets	$	63,547		$	65,164
Valuation allowance		(62,573	)		(62,845	)
Deferred tax asset, net of valuation allowance	$	974		$	2,319

Deferred Tax Liabilities
Adoption of ASC 842 – ROU Asset		(11	)		(1,360	)
Patent cost		(943	)		(917	)
Other deferred tax liabilities		(20	)		(42	)
Total deferred tax liabilities	$	(974	)	$	(2,319	)
Net deferred tax asset (liability)	$	-		$	-

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

		2021
	Years Ended
	October 31, 2021			October 31, 2020
US Federal statutory rate		21.00	%		21.00	%
State income tax, net of federal benefit		(0.73	)		5.48
Merger costs		(1.68	)		0.00
Other permanent differences		(0.02	)		(0.05	)
Research and development credits		3.09			1.73
Warrant Liability		1.14			0.00
Foreign taxes		(0.28	)		(0.19	)
Change in valuation allowance		1.52			(22.82	)
Stock option expirations		(24.32	)		(5.33	)
Income tax (provision) benefit		(0.28	)%		(0.19	)%

The “Foreign taxes” income tax expense in the consolidated statement of operations for both the years ended October 31, 2021 and 2020 pertain to a Taiwan Excise tax of $50,000 levied in connection with the GBP Revenue.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Property, Plant and Equipment [Line Items]
Cash equivalent	$ 17.2	$ 17.1
Concentration of credit risk amount	$ 41.6
Number of securities included in computation of basic earnings per share	31,119,343	1,415,550
Exercise price	$ 0
Warrant [Member]
Property, Plant and Equipment [Line Items]
Number of securities included in computation of basic earnings per share		327,338
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Estimated useful life of intangible assets	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	10 years
Estimated useful life of intangible assets	20 years

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	31,119,343	1,415,550
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	30,225,397	398,226
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	893,946	1,011,768
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		5,556

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Income Statement [Abstract]
Revenue	$ 3,240,000	$ 253,000
Operating expenses:
Research and development expenses	10,562,000	15,612,000
General and administrative expenses	11,464,000	11,090,000
Total operating expenses	22,026,000	26,702,000
Loss from operations	(18,786,000)	(26,449,000)
Other income (expense):
Interest income	5,000	110,000
Net changes in fair value of derivative liabilities	970,000
Loss on shares issued in settlement of warrants		(77,000)
Other expense	(1,000)	(3,000)
Net loss before income tax benefit	(17,812,000)	(26,419,000)
Income tax expense	50,000	50,000
Net loss	$ (17,862,000)	$ (26,469,000)
Net loss per common share, basic and diluted	$ (0.14)	$ (0.43)
Weighted average number of common shares outstanding, basic and diluted	129,090,709	61,003,839

INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Goodwill [Line Items]
Expiration of patents description	The expirations of the existing patents range from 2021 to 2039
Book value patent applications, net	$ 94	$ 1,725
Intangible asset amortization expense	273	337
General and Administrative Expense [Member]
Goodwill [Line Items]
Book value patent applications, net	100	1,700
Intangible asset amortization expense	$ 300	$ 300

ACCRUED EXPENSES (Tables)

12 Months Ended

Oct. 31, 2021

Payables and Accruals [Abstract]

SUMMARY OF ACCRUED EXPENSES

The following table represents the major components of accrued expenses (in thousands):

SUMMARY OF ACCRUED EXPENSES

	2021		2020
	October 31,
	2021		2020
Salaries and other compensation	$	55	$	737
Vendors		2,168		671
Professional fees		613		329
Total accrued expenses	$	2,836	$	1,737

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)

12 Months Ended

Oct. 31, 2021

Subsidiary, Sale of Stock [Line Items]

SCHEDULE OF OUTSTANDING WARRANTS

Exercise Price			Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	281.25			25	N/A	Other Warrants
$	2.80	*		327,338	July 2024	July 2019 Public Offering
$	0.30			70,297	September 2024	September 2018 Public Offering
$	0.35			4,578,400	November 2025	November 2020 Public Offering
$	0.70			11,244,135	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	0.70			14,005,202	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants
	Grand Total			30,225,997

*	During the year ended October 31, 2021, the cashless exercise provision of these warrants expired and the exercise price adjusted to $2.80.

As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	281.25		25	N/A	Other Warrants
$	-		327,338	July 2024	July 2019 Public Offering
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

SCHEDULE OF WARRANTS ACTIVITY

A summary of warrant activity was as follows (In thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2019		432,142		$	0.08		4.76	$	114,069
Issued		5,000,000			1.25		-
Exercised *		(33,916	)		0.02
Exchanged		(5,000,000	)		1.25
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		48,254,606			0.48		-
Exercised		(18,427,435	)		0.20
Outstanding and exercisable warrants at October 31, 2021		30,225,397		$	0.67		4.63	$	631,089

*	Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the September 2018 Public Offering warrants at October 31, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	October 31, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.485		$	0.34
Expected Term		2.87 years			3.87 years
Volatility %		123	%		106	%
Risk Free Rate		0.77	%		0.29	%

Private Placement [Member]

Subsidiary, Sale of Stock [Line Items]

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at October 31, 2021 and April 14, 2021 (issuance date), the Company used the following inputs in its Black Scholes model:

	October 31, 2021			April 14, 2021
Exercise Price	$	0.70		$	0.70
Stock Price	$	0.485		$	0.57
Expected Term		5.00 years			5.00 years
Volatility %		106	%		106	%
Risk Free Rate		1.18	%		0.85	%

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
Consolidated Statement of Cash Flows - USD ($)	Oct. 31, 2021	Oct. 31, 2020
OPERATING ACTIVITIES
Net loss	$ (17,862,000)	$ (26,469,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	566,000	891,000
Employee stock purchase plan expense		1,000
(Gain) loss on change in value of warrant liability	(970,000)
Loss on shares issued in settlement of warrants		77,000
Loss on disposal of property and equipment	1,439,000
Loss on write-down of property and equipment		1,060,000
Abandonment of intangible assets	94,000	1,725,000
Depreciation expense	387,000	897,000
Amortization of deferred offering costs		644,000
Amortization expense of intangible assets	273,000	337,000
Amortization expense of right-of-use assets	330,000	744,000
Net gain on write-off of right-of-use asset and lease liability	(116,000)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and deferred expenses	1,030,000	1,113,000
Other assets	171,000	1,000
Accounts payable and accrued expenses	776,000	(2,307,000)
Deferred revenue	(165,000)	165,000
Operating lease liabilities	(1,392,000)	(819,000)
Net cash used in operating activities	(15,439,000)	(21,940,000)
INVESTING ACTIVITIES
Proceeds from disposal of property and equipment	449,000
Cost of intangible assets	(460,000)	(748,000)
Net cash used in investing activities	(11,000)	(748,000)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock and warrants	28,115,000	15,496,000
Proceeds from warrant exercises	3,771,000
Proceeds from employee stock purchase plan		7,000
Employee tax withholdings paid on equity awards		(1,000)
Tax shares sold to pay for employee tax withholdings on equity awards		1,000
Net cash provided by financing activities	31,886,000	15,503,000
Net increase (decrease) in cash and cash equivalents	16,436,000	(7,185,000)
Cash and cash equivalents at beginning of year	25,178,000	32,363,000
Cash and cash equivalents at end of year	41,614,000	25,178,000
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes	50,000	50,000
Supplemental Schedule of Noncash Investing and Financing Activities
Shares issued in settlement of warrants		77,000
Commitment fee shares issued for equity line		644,000
Cashless exercise of warrants		2,000
Reassessment of the lease term	$ 43,000

SHARE BASED COMPENSATION

12 Months Ended

Oct. 31, 2021

Share-based Payment Arrangement [Abstract]

SHARE BASED COMPENSATION

8. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the consolidated statement of operations by expense category for the years ended October 31, 2021 and 2020 (in thousands):

	Year Ended October 31,
	2021		2020
Research and development	$	164	$	308
General and administrative		402		583
Total	$	566	$	891

Amendments

The Advaxis, Inc. 2015 Incentive Plan (the “2015 Plan”) was originally ratified and approved by the Company’s stockholders on May 27, 2015. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number of shares of common stock that may be issued under the 2015 Plan is 240,000 shares, plus a number of additional shares (not to exceed 43,333) underlying awards outstanding as of the effective date of the 2015 Plan under the prior plan that thereafter terminate or expire unexercised, or are cancelled, forfeited or lapse for any reason.

On January 1, 2020, 166,667 shares were added to the 2015 Plan.

At the Annual Meeting of Stockholders of the Company held on May 4, 2020, the Company’s stockholders voted to approve an amendment to increase the number of shares authorized for issuance under the 2015 Plan from 877,744 shares to 6,000,000 shares.

On January 1, 2021, 166,667 shares were added to the 2015 Plan.

As of October 31, 2021, there were 5,127,985 shares available for issuance under the 2015 Plan.

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the fiscal year ended October 31, 2021 and 2020 is as follows:

	Number of RSU’s			Weighted-Average Grant Date Fair Value
Balance at October 31, 2019		14,706		$	47.62
Vested		(8,870	)		60.59
Cancelled		(280	)		98.80
Balance at October 31, 2020		5,556		$	24.32
Vested		(5,555	)		24.30
Cancelled		(1	)		125.25
Balance at October 31, 2021		-		$	-

The fair value of the RSUs as of the respective vesting dates was approximately $3,000 and $5,000 for the years ended October 31, 2021 and 2020, respectively.

Employee Stock Awards

Common stock issued to executives and employees related to vested incentive retention awards and employment inducements totaled 5,555 shares and 8,870 shares during the years ended October 31, 2021 and 2020, respectively. Total stock compensation expense associated with these awards for the years ended October 31, 2021 and 2020 was approximately $67,000 and $0.2 million, respectively.

Stock Options

A summary of changes in the stock option plan for the years ended October 31, 2021 and 2020 is as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2019		560,490		$	71.56		7.34	$	1
Granted		645,000			0.61
Cancelled or expired		(193,722	)		34.47
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Exercised		(333	)		0.30
Cancelled or expired		(167,489	)		98.93
Outstanding as of October 31, 2021		893,946		$	19.32		7.8	$	27
Vested and exercisable at October 31, 2021		456,506		$	37.03		6.98	$	15

During the year ended October 31, 2021, the Company granted stock options to purchase 50,000 shares of its common stock to an employee. The stock options have a ten-year term, vest over three years from the date of grant, and have an exercise price of $0.39. During the year ended October 31, 2020, the Company granted stock options to purchase 580,000 and 65,000 shares of its common stock to employees and directors, respectively. The stock options issued to employees have a ten-year term, vest over three years, and have an exercise price of $0.49 to $0.66. The stock options issued to directors have a ten-year term, vest over three years, and have an exercise price of $0.66.

The weighted average grant date fair value of options granted during the fiscal years ended October 31, 2021 and 2020 was $0.32 and $0.48, respectively.

The total intrinsic value of options exercised during the fiscal years ended October 31, 2021 and 2020 was $162 and $0.

Total compensation cost related to the Company’s outstanding stock options, recognized in the consolidated statement of operations for the years ended October 31, 2021 and 2020 was approximately $0.5 million and $0.7 million, respectively.

As of October 31, 2021, there was approximately $0.2 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.61 years.

The following table summarizes information about the outstanding and exercisable stock options at October 31, 2021:

Options Outstanding										Options Exercisable
				Weighted		Weighted						Weighted		Weighted
				Average		Average						Average		Average
Exercise		Number		Remaining		Exercise		Intrinsic		Number		Remaining		Exercise		Intrinsic
Price Range		Outstanding		Contractual		Price		Value		Exercisable		Contractual		Price		Value
$	.30-$10.00		727,879		8.43	$	1.06	$	27		290,439		8.23	$	1.40	$	15
$	10.01-$100.00		90,432		6.22	$	29.02	$	-		90,432		6.22	$	29.02	$	-
$	100.01-$200.00		50,938		3.47	$	162.17	$	-		50,938		3.47	$	162.17	$	-
$	200.01-$277.5		24,697		2.22	$	227.35	$	-		24,697		2.22	$	227.35	$	-

The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2021 and 2020 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s common stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s common stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating expected lives of the options. The Company used their own historical volatility in determining the volatility to be used. The expected term of the stock option grants was calculated using the “simplified” method in accordance with the SEC Staff Accounting Bulletin 107. The “simplified” method was used since the Company believes its historical data does not provide a reasonable basis upon which to estimate expected term and the Company does not have enough option exercise data from its grants issued to support its own estimate as a result of vesting terms and changes in the stock price. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

The following table provides the weighted average fair value of stock options granted to directors and employees and the related assumptions used in the Black-Scholes model:

	Year Ended
	October 31, 2021			October 31, 2020
Expected term		6 years			5.50-6.50 years
Expected volatility		103.27	%		100.27-105.21	%
Expected dividends		0	%		0	%
Risk free interest rate		0.53	%		0.36-0.62	%

Employee Stock Purchase Plan

The Advaxis, Inc. 2018 Employee Stock Purchase Plan (ESPP) was approved by the Company’s shareholders on March 21, 2018. The 2018 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2018 ESPP beginning May 1, 2018. 1,000,000 shares of the Company’s Common stock were reserved for issuance under the 2018 ESPP.

During the fiscal years ended October 31, 2021 and 2020, the Company issued 1,000 and 14,148 shares, respectively, under the 2018 ESPP. In July 2021, the ESPP was terminated.

SCHEDULE OF WARRANTS ACTIVITY (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Common Stock Purchase Warrants And Warrant Liability
Warrants, Outstanding and exercisable warrants, Beginning balance	398,226	432,142
Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning	$ 0.08	$ 0.08
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning balance	3 years 9 months 3 days	4 years 9 months 3 days
Aggregate Intrinsic Value, Beginning	$ 110,640	$ 114,069
Warrants, Issued	48,254,606	5,000,000
Weighted Average Exercise Price, Issued	$ 0.48	$ 1.25
Warrants, Exercised	(18,427,435)	(33,916)
Weighted Average Exercise Price, Exercised	$ 0.20	$ 0.02
Warrants, Exchanged		(5,000,000)
Weighted Average Exercise Price, Exchanged		$ 1.25
Warrants, Outstanding and exercisable warrants, Ending balance	30,225,397	398,226
Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending	$ 0.67	$ 0.08
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	4 years 7 months 17 days
Aggregate Intrinsic Value, Ending	$ 631,089	$ 110,640

PROPERTY AND EQUIPMENT

12 Months Ended

Oct. 31, 2021

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

3. PROPERTY AND EQUIPMENT

Property and equipment consist of the following (in thousands):

SCHEDULE OF PROPERTY AND EQUIPMENT

	2021			2020
	October 31,
	2021			2020
Leasehold improvements	$	-		$	2,335
Laboratory equipment		179			1,218
Furniture and fixtures		-			744
Computer equipment		241			409
Construction in progress		-			19
Total property and equipment		420			4,725
Accumulated depreciation and amortization		(302	)		(2,332	)
Net property and equipment	$	118		$	2,393

Depreciation expense for the years ended October 31, 2021 and 2020 was approximately $0.4 million and $0.9 million, respectively. During the year ended October 31, 2021, the Company incurred a loss on disposal of equipment of approximately $1.4 million, $0.9 million of which is reflected in the research and development expenses and $0.5 million of which is reflected in the general and administrative expenses in the consolidated statement of operations.

Management has reviewed its property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. During the years ended October 31, 2021 and 2020, the Company recorded impairment losses on idle laboratory equipment of $0 and $1.1 million, respectively, that was charged to research and development expenses in the consolidated statement of operations. Fair value for the idle assets was determined by a quoted purchase price for the assets.

CONTINGENCIES

12 Months Ended

Oct. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

CONTINGENCIES

10. CONTINGENCIES

Legal Proceedings

Atachbarian

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14A-9 promulgated thereunder by allegedly failing to disclose certain matters in the Registration Statement. On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company filed a Form 8-K with the SEC in which it made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company reached a settlement agreement, which is recorded in general and administrative expenses in the consolidated income statement.

Purported Stockholder Claims Related to Biosight Transaction

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an Amendment to the Registration Statement and on November 8, 2021, the Company filed a Form 8-K with the SEC in which it made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made a settlement demand. The Company believes it has adequately accrued for a settlement, which is recorded in general and administrative expenses in the consolidated income statement.

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Merger contained alleged material misstatements and/or omissions in violation of federal law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

Stendhal

On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”). In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest.

From October 21-23, 2019, an evidentiary hearing for the arbitration was conducted. On April 1, 2020, the Arbitrator issued a final award denying Stendhal’s claim in full. The Arbitrator found that the Company had not repudiated the Agreement and did not owe Stendhal damages, fees, or interest associated with the arbitration. The Arbitrator also denied the Company’s claim that Stendhal breached its obligations to the Company. The parties were ordered to bear their own attorneys’ fees and evenly split administrative fees and expenses for the arbitration.

SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANT LIABILITIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Beginning balance	$ 17	$ 19
Warrants issued	5,882
Warrant exercises		(2)
Change in fair value	(970)
Ending balance	$ 4,929	$ 17

SCHEDULE OF LEASE EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Leases
Operating lease cost	$ 1,302	$ 1,158
Short-term lease cost	14	320
Variable lease cost	180	547
Total lease expense	$ 1,496	$ 2,025

SCHEDULE OF WARRANTS ACTIVITY (Details) (Parenthetical)	12 Months Ended
SCHEDULE OF WARRANTS ACTIVITY (Details) (Parenthetical)	Oct. 31, 2021 shares
Cashless warrant exercise	32,500
Warrant [Member]
Advaxis public offerings, net of offering costs, shares	32,500

SHARE BASED COMPENSATION (Tables)

12 Months Ended

Oct. 31, 2021

Share-based Payment Arrangement [Abstract]

SUMMARY OF SHARE BASED COMPENSATION EXPENSE

The following table summarizes share-based compensation expense included in the consolidated statement of operations by expense category for the years ended October 31, 2021 and 2020 (in thousands):

	Year Ended October 31,
	2021		2020
Research and development	$	164	$	308
General and administrative		402		583
Total	$	566	$	891

SUMMARY OF RSU ACTIVITY AND RELATED INFORMATION

A summary of the Company’s RSU activity and related information for the fiscal year ended October 31, 2021 and 2020 is as follows:

	Number of RSU’s			Weighted-Average Grant Date Fair Value
Balance at October 31, 2019		14,706		$	47.62
Vested		(8,870	)		60.59
Cancelled		(280	)		98.80
Balance at October 31, 2020		5,556		$	24.32
Vested		(5,555	)		24.30
Cancelled		(1	)		125.25
Balance at October 31, 2021		-		$	-

SUMMARY OF CHANGES IN STOCK OPTION PLAN

A summary of changes in the stock option plan for the years ended October 31, 2021 and 2020 is as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2019		560,490		$	71.56		7.34	$	1
Granted		645,000			0.61
Cancelled or expired		(193,722	)		34.47
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Exercised		(333	)		0.30
Cancelled or expired		(167,489	)		98.93
Outstanding as of October 31, 2021		893,946		$	19.32		7.8	$	27
Vested and exercisable at October 31, 2021		456,506		$	37.03		6.98	$	15

SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS

The following table summarizes information about the outstanding and exercisable stock options at October 31, 2021:

Options Outstanding										Options Exercisable
				Weighted		Weighted						Weighted		Weighted
				Average		Average						Average		Average
Exercise		Number		Remaining		Exercise		Intrinsic		Number		Remaining		Exercise		Intrinsic
Price Range		Outstanding		Contractual		Price		Value		Exercisable		Contractual		Price		Value
$	.30-$10.00		727,879		8.43	$	1.06	$	27		290,439		8.23	$	1.40	$	15
$	10.01-$100.00		90,432		6.22	$	29.02	$	-		90,432		6.22	$	29.02	$	-
$	100.01-$200.00		50,938		3.47	$	162.17	$	-		50,938		3.47	$	162.17	$	-
$	200.01-$277.5		24,697		2.22	$	227.35	$	-		24,697		2.22	$	227.35	$	-

SUMMARY OF FAIR VALUE OF STOCK OPTIONS GRANTED OF BSM

The following table provides the weighted average fair value of stock options granted to directors and employees and the related assumptions used in the Black-Scholes model:

	Year Ended
	October 31, 2021			October 31, 2020
Expected term		6 years			5.50-6.50 years
Expected volatility		103.27	%		100.27-105.21	%
Expected dividends		0	%		0	%
Risk free interest rate		0.53	%		0.36-0.62	%

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Leases
Cash paid for operating lease liabilities	$ 547	$ 1,233

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative)			1 Months Ended				6 Months Ended	12 Months Ended
	Oct. 16, 2021 USD ($) $ / shares shares	Nov. 27, 2020 shares	Mar. 31, 2021 USD ($)	Nov. 30, 2020 USD ($) shares	May 31, 2020 USD ($)	Jan. 31, 2020 USD ($) shares	Oct. 31, 2020 USD ($) $ / shares shares	Oct. 31, 2021 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) $ / shares shares	Jun. 03, 2021 shares	Jun. 01, 2021 shares	Apr. 30, 2021 $ / shares	Apr. 14, 2021 $ / shares
Number of warrants to purchase common stock							398,226	30,225,997	398,226
Warrant exercise price per share \| $ / shares							$ 0.372	$ 0.30	$ 0.372
Proceeds from Issuance Initial Public Offering \| $			$ 762,000	$ 8,500,000	$ 40,000,000	$ 9,600,000	$ 1,583,000
Loss on shares issued in settlement of warrants \| $	$ 77,000								$ (77,000)
Common Stock, Par or Stated Value Per Share \| $ / shares							$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized							170,000,000	170,000,000	170,000,000	300,000,000	170,000,000
Fair value of the warrant liability \| $							$ 17,000	$ 4,900,000	$ 17,000
Income on fair value of warrants \| $								1,000,000.0
Income on fair value of warrants \| $								(970,000)
Measurement Input, Exercise Price [Member]
Warrants, measurement input	1.25
Measurement Input, Share Price [Member]
Warrants, measurement input	0.406
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term	4 years 9 months 3 days
Measurement Input, Price Volatility [Member]
Warrants, measurement input fair value, percentage	101.18%
Measurement Input, Risk Free Interest Rate [Member]
Warrants, measurement input fair value, percentage	0.32%
Private Exchange Agreement [Member]
Number of warrants to purchase common stock	5,000,000
Warrant exercise price per share \| $ / shares	$ 1.25
Warrants and Rights Outstanding, Maturity Date	Jul. 21, 2025
Private Exchange Agreement [Member] \| Investor [Member]
Advaxis public offerings, net of offering costs, shares	3,000,000
IPO [Member]
Proceeds from Issuance Initial Public Offering \| $								$ 3,800,000
Advaxis public offerings, net of offering costs, shares		26,666,666
Common Stock, Shares Authorized								300,000,000
Private Placement [Member]
Number of warrants to purchase common stock				15,333,332
Warrant exercise price per share \| $ / shares								$ 0.70
Warrants and Rights Outstanding, Term				5 years									5 years
Minimum [Member]
Warrant exercise price per share \| $ / shares							$ 0		$ 0
Maximum [Member]
Warrant exercise price per share \| $ / shares							$ 281.25		$ 281.25
Maximum [Member] \| Private Placement [Member]
Number of warrants to purchase common stock						5,000,000
Warrant [Member]
Number of warrants to purchase common stock								30,225,397
Warrant exercise price per share \| $ / shares								$ 2.80
Advaxis public offerings, net of offering costs, shares								32,500
Warrant [Member] \| IPO [Member]
Number of warrants to purchase common stock								10,754,932
Warrant [Member] \| Minimum [Member]
Warrant exercise price per share \| $ / shares								$ 0.30
Warrant [Member] \| Maximum [Member]
Warrant exercise price per share \| $ / shares								$ 281.25
Equity Warrants [Member]
Number of warrants to purchase common stock							327,363	16,149,898	327,363
Warrants outstanding							398,226	30,225,397	398,226
Common Stock [Member]
Advaxis public offerings, net of offering costs, shares								49,130,113	12,489,104
Common Stock [Member] \| IPO [Member]
Number of warrants to purchase common stock								10,754,932
Pre Funded Warrant [Member]
Warrant exercise price per share \| $ / shares												$ 0.70
Pre Funded Warrant [Member] \| IPO [Member]
[custom:PrefundedWarrantsToPurchaseCommonSharesExercised-0]								7,671,937
[custom:PrefundedWarrantsToPurchaseCommonExchangeShares-0]								7,671,937
Warrant Liability [Member]
Number of warrants to purchase common stock							70,863		70,863
Warrant exercise price per share \| $ / shares							$ 0.37	$ 0.30	$ 0.37
Warrants outstanding							398,226		398,226
Warrant Liability [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term							3 years 10 months 13 days	2 years 10 months 13 days	3 years 10 months 13 days
Warrant Liability [Member] \| Measurement Input, Price Volatility [Member]
Warrants, measurement input							106	123	106
Warrant Liability [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants, measurement input							0.29	0.77	0.29
Warrant Liability [Member] \| Private Placement [Member]
Number of warrants to purchase common stock								14,075,499
Warrant exercise price per share \| $ / shares								$ 0.70					$ 0.70
Warrants outstanding								30,225,397
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term								5 years
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Price Volatility [Member]
Warrants, measurement input								106					106
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants, measurement input								1.18					0.85
Warrant Liability [Member] \| Minimum [Member]
Warrant exercise price per share \| $ / shares								$ 0.30
Warrant Liability [Member] \| Maximum [Member]
Warrant exercise price per share \| $ / shares								$ 22.50

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)	Oct. 31, 2021 $ / shares	Oct. 16, 2021	Apr. 14, 2021 $ / shares	Nov. 30, 2020	Oct. 31, 2020 $ / shares
Exercise Price	$ 0.30				$ 0.372
Stock Price	0
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term		4 years 9 months 3 days
Private Placement [Member]
Exercise Price	0.70
Warrants and Rights Outstanding, Term			5 years	5 years
Warrant Liability [Member]
Exercise Price	0.30				0.37
Stock Price	$ 0.485				$ 0.34
Warrant Liability [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term	2 years 10 months 13 days				3 years 10 months 13 days
Warrant Liability [Member] \| Measurement Input, Price Volatility [Member]
Measurement input percentage	123				106
Warrant Liability [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage	0.77				0.29
Warrant Liability [Member] \| Private Placement [Member]
Exercise Price	$ 0.70		$ 0.70
Stock Price	$ 0.485		$ 0.57
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term	5 years
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Price Volatility [Member]
Measurement input percentage	106		106
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage	1.18		0.85

LEASES (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
LEASES (Details Narrative) - USD ($)	Mar. 26, 2021	Mar. 25, 2021	Oct. 31, 2021	Oct. 31, 2020
Leases
Lease expiration date			Nov. 30, 2025
Security Deposit			$ 182,000
Lease termination	$ 1,000,000
Net payment for termination fee	818,000
Operating lease, Right of use asset	4,500,000	$ 43,000	40,000	$ 4,839,000
Operating lease liability	5,600,000	$ 43,000	$ 40,000	$ 6,017,000
Net gain on Leases	100,000
Rent paid	$ 29,000
Lease Term		Mar. 25, 2022
Renewal Term		Mar. 25, 2023

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) - USD ($)	Oct. 31, 2021	Mar. 26, 2021	Mar. 25, 2021	Oct. 31, 2020
Leases
2022	$ 29,000
2023	12,000
Total minimum lease payments	41,000
Less: Imputed interest	(1,000)
Total	$ 40,000	$ 5,600,000	$ 43,000	$ 6,017,000

Consolidated Balance Sheets - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Current assets:
Cash and cash equivalents	$ 41,614,000	$ 25,178,000
Deferred expenses		1,808,000
Prepaid expenses and other current assets	1,643,000	865,000
Total current assets	43,257,000	27,851,000
Property and equipment (net of accumulated depreciation)	118,000	2,393,000
Intangible assets (net of accumulated amortization)	3,354,000	3,261,000
Operating right-of-use asset (net of accumulated amortization)	40,000	4,839,000
Other assets	11,000	182,000
Total assets	46,780,000	38,526,000
Current liabilities:
Accounts payable	87,000	410,000
Accrued expenses	2,836,000	1,737,000
Current portion of operating lease liability	28,000	962,000
Deferred revenue		165,000
Common stock warrant liability	4,929,000	17,000
Total current liabilities	7,880,000	3,291,000
Operating lease liability, net of current portion	12,000	5,055,000
Total liabilities	7,892,000	8,346,000
Contingencies – Note 10
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2021 and 2020. Liquidation preference of $0 at October 31, 2021 and 2020.
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 and 78,074,023 shares issued and outstanding at October 31, 2021 and 2020.	146,000	78,000
Additional paid-in capital	467,342,000	440,840,000
Accumulated deficit	(428,600,000)	(410,738,000)
Total stockholders’ equity	38,888,000	30,180,000
Total liabilities and stockholders’ equity	$ 46,780,000	$ 38,526,000

SCHEDULE OF OUTSTANDING WARRANTS (Details) - $ / shares

12 Months Ended

Oct. 31, 2021

Oct. 31, 2020

Offsetting Assets [Line Items]

Exercise Price

$ 0.30

$ 0.372

Number of Shares Underlying Warrants

30,225,997

398,226

Warrant [Member]

Offsetting Assets [Line Items]

Exercise Price

$ 2.80

Number of Shares Underlying Warrants

30,225,397

Exercise Price Range One [Member]

Offsetting Assets [Line Items]

Exercise Price

$ 281.25

Number of Shares Underlying Warrants

Type of Financing

Other Warrants

Exercise Price Range Two [Member]

Offsetting Assets [Line Items]

Exercise Price

$ 2.80

^[1]

Number of Shares Underlying Warrants

327,338

Type of Financing

July 2019 Public Offering

Expiration Date

July 2024

Exercise Price Range Three [Member]

Offsetting Assets [Line Items]

Exercise Price

$ 0.30

$ 0.372

Number of Shares Underlying Warrants

70,297

70,863

Type of Financing

September 2018 Public Offering

Expiration Date

September 2024

Exercise Price Range Four [Member]

Offsetting Assets [Line Items]

Exercise Price

$ 0.35

Number of Shares Underlying Warrants

4,578,400

Type of Financing

November 2020 Public Offering

Expiration Date

November 2025

Exercise Price Range Five [Member]

Offsetting Assets [Line Items]

Exercise Price

$ 0.70

Number of Shares Underlying Warrants

11,244,135

Type of Financing

April 2021 Registered Direct Offering (Accompanying Warrants)

Expiration Date

April 2026

Exercise Price Range Six [Member]

Offsetting Assets [Line Items]

Exercise Price

$ 0.70

Number of Shares Underlying Warrants

14,005,202

Type of Financing

April 2021 Private Placement (Private Placement Warrants

Expiration Date

5 years after the date such warrants become exercisable, if ever

[1]	During the year ended October 31, 2021, the cashless exercise provision of these warrants expired and the exercise price adjusted to $2.80.

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Depreciation expense	$ 387,000	$ 897,000
Loss on disposal of equipment	1,439,000
Laboratory Equipment [Member]
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Impairment loss on idle laboratory equipment	0	$ 1,100,000
Research and Development Expense [Member]
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Loss on disposal of equipment	900,000
General and Administrative Expense [Member]
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Loss on disposal of equipment	$ 500,000

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Oct. 31, 2021

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment consist of the following (in thousands):

SCHEDULE OF PROPERTY AND EQUIPMENT

	2021			2020
	October 31,
	2021			2020
Leasehold improvements	$	-		$	2,335
Laboratory equipment		179			1,218
Furniture and fixtures		-			744
Computer equipment		241			409
Construction in progress		-			19
Total property and equipment		420			4,725
Accumulated depreciation and amortization		(302	)		(2,332	)
Net property and equipment	$	118		$	2,393

SHARE BASED COMPENSATION (Details Narrative) - USD ($)		12 Months Ended
SHARE BASED COMPENSATION (Details Narrative) - USD ($)	Mar. 21, 2019	Oct. 31, 2021	Oct. 31, 2020	Jun. 03, 2021	Jun. 01, 2021	May 04, 2021	Jan. 02, 2021	Jan. 02, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized		170,000,000	170,000,000	300,000,000	170,000,000
Stock compensation expense		$ 566,000	$ 891,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000	645,000
Fair value, grant		$ 0.32	$ 0.48
Intrinsic value of options exercised		$ 162	$ 0
Share-based Payment Arrangement, Expense		500,000	$ 700,000
Unrecognized cost		$ 200,000
Vesting period		1 year 7 months 9 days
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			65,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price			$ 0.66
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000	580,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term		10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price		$ 0.39
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of equity purchases value		$ 3,000	$ 5,000
Employee Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, common stock, shares		5,555	8,870
Stock compensation expense		$ 67,000	$ 200,000
Maximum [Member] \| Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price			$ 0.66
Minimum [Member] \| Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price			$ 0.49
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance under plan		5,127,985					166,667	166,667
2015 Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized						6,000,000
2015 Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized						877,744
2018 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase plan description	the Company’s shareholders on March 21, 2018. The 2018 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2018 ESPP beginning May 1, 2018. 1,000,000 shares of the Company’s Common stock were reserved for issuance under the 2018 ESPP.
Advaxis public offerings, net of offering costs, shares		1,000	14,148
Stock Split [Member] \| 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock		240,000
Stock Split [Member] \| 2015 Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock		43,333

LEASES (Tables)

12 Months Ended

Oct. 31, 2021

Leases

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES

Supplemental balance sheet information related to leases as of October 31 was as follows (in thousands):

	October 31, 2021		October 31, 2020
Operating leases:
Operating lease right-of-use assets	$	40	$	4,839

Operating lease liability	$	28	$	962
Operating lease liability, net of current portion		12		5,055
Total operating lease liabilities	$	40	$	6,017

SCHEDULE OF LEASE EXPENSES

Supplemental lease expense related to leases was as follows (in thousands):

SCHEDULE OF LEASE EXPENSES

Lease Cost (in thousands)	Statements of Operations Classification	For the Fiscal Year Ended October 31, 2021		For the Fiscal Year Ended October 31, 2020
Operating lease cost	General and administrative	$	1,302	$	1,158
Short-term lease cost	General and administrative		14		320
Variable lease cost	General and administrative		180		547
Total lease expense		$	1,496	$	2,025

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES

Other information related to leases where the Company is the lessee is as follows:

	October 31, 2021			October 31, 2020
Weighted-average remaining lease term		1.4 years			5.1 years
Weighted-average discount rate		3.79	%		6.5	%

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES

Supplemental cash flow information related to operating leases was as follows:

	For the Fiscal Year Ended October 31, 2021		For the Fiscal Year Ended October 31, 2020
Cash paid for operating lease liabilities	$	547	$	1,233

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES

Future minimum lease payments under non-cancellable leases as of October 31, 2021 were as follows:

Fiscal Year ending October 31,
2022	$	29
2023		12
Total minimum lease payments		41
Less: Imputed interest		(1	)
Total	$	40

EMPLOYEE BENEFIT PLAN (Details Narrative) $ in Millions	12 Months Ended
EMPLOYEE BENEFIT PLAN (Details Narrative) $ in Millions	Oct. 31, 2020 USD ($)
401(k) Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$ 0.1

SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 566	$ 891
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	164	308
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 402	$ 583

SCHEDULE OF EXPECTED TAX (EXPENSE) BENEFIT BASED ON STATUTORY RATE WITH ACTUAL TAX EXPENSE BENEFIT (Details)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
US Federal statutory rate	21.00%	21.00%
State income tax, net of federal benefit	(0.73%)	5.48%
Merger costs	(1.68%)	0.00%
Other permanent differences	(0.02%)	(0.05%)
Research and development credits	3.09%	1.73%
Warrant Liability	1.14%	0.00%
Foreign taxes	(0.28%)	(0.19%)
Change in valuation allowance	1.52%	(22.82%)
Stock option expirations	(24.32%)	(5.33%)
Income tax (provision) benefit	(0.28%)	(0.19%)

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) - USD ($)	Oct. 31, 2021	Mar. 26, 2021	Mar. 25, 2021	Oct. 31, 2020
Leases
Operating lease right-of-use assets	$ 40,000	$ 4,500,000	$ 43,000	$ 4,839,000
Operating lease liability	28,000			962,000
Operating lease liability, net of current portion	12,000			5,055,000
Total operating lease liabilities	$ 40,000	$ 5,600,000	$ 43,000	$ 6,017,000

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Oct. 31, 2021	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Leasehold improvements		$ 2,335
Laboratory equipment	179	1,218
Furniture and fixtures		744
Computer equipment	241	409
Construction in progress		19
Total property and equipment	420	4,725
Accumulated depreciation and amortization	(302)	(2,332)
Net property and equipment	$ 118	$ 2,393

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Oct. 31, 2021

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), determining the Incremental Borrowing Rate (“IBR”) for calculating Right-Of-Use (“ROU”) assets and lease liabilities, deferred expenses, deferred revenue, the fair value of options, warrants and related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Revenue Recognition

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.

Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Exclusive Licenses. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods.

Milestone Payments. At the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Collaborative Arrangements

The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. As of October 31, 2021 and 2020, the Company had cash equivalents of approximately $17.2 million and $17.1 million, respectively.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $41.6 million is subject to credit risk at October 31, 2021. The Company has not experienced any losses in such accounts.

Deferred Expenses

Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the consolidated statement of operations as the research and development activity is performed.

Property and Equipment

Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three to ten years.

When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible assets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives ranging from three to 20 years. Patent application costs are written-off if the application is rejected, withdrawn or abandoned.

Impairment of Long-Lived Assets

The Company periodically assesses the carrying value of intangible and other long-lived assets, and whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. The assets are considered to be impaired if the Company determines that the carrying value may not be recoverable based upon its assessment, which includes consideration of the following events or changes in circumstances:

	●	the asset’s ability to continue to generate income from operations and positive cash flow in future periods;
	●	loss of legal ownership or title to the asset(s);
	●	significant changes in the Company’s strategic business objectives and utilization of the asset(s); and
	●	the impact of significant negative industry or economic trends.

If the assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Fair value is determined by the application of discounted cash flow models to project cash flows from the assets. In addition, the Company bases estimates of the useful lives and related amortization or depreciation expense on its subjective estimate of the period the assets will generate revenue or otherwise be used by it. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less selling costs. The Company also periodically reviews the lives assigned to long-lived assets to ensure that the initial estimates do not exceed any revised estimated periods from which the Company expects to realize cash flows from its assets.

Leases

At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the consolidated balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the consolidated balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.

Net Income (Loss) per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share (as of October 31, 2020, 327,338 warrants are included in the basic earnings per share computation because the exercise price is $0):

	As of October 31,
	2021		2020
Warrants		30,225,397		398,226
Stock options		893,946		1,011,768
Restricted stock units		-		5,556
Total		31,119,343		1,415,550

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs.

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the consolidated statement of operations, depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants.

Fair Value of Financial Instruments

The carrying value of financial instruments, including cash and cash equivalents and accounts payable, approximated fair value as of the balance sheet date presented, due to their short maturities.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Monte Carlo simulation model and the Black Scholes model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Sequencing Policy

The Company adopted a sequencing policy under ASC 815-40-35, if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. Certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

Recent Accounting Standards

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The standard will apply as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted and is not material to the financial results of the Company.

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. We are currently evaluating the impact of this standard on our consolidated financial statements.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

EMPLOYEE BENEFIT PLAN

12 Months Ended

Oct. 31, 2021

Retirement Benefits [Abstract]

EMPLOYEE BENEFIT PLAN

14. EMPLOYEE BENEFIT PLAN

The Company sponsors a 401(k) Plan. Employees become eligible for participation upon the start of employment. Participants may elect to have a portion of their salary deferred and contributed to the 401(k) Plan up to the limit allowed under the Internal Revenue Code. The Company makes a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year. The Company made matching contributions which amounted to approximately $0.1 million for each of the years ended October 31, 2021 and 2020, respectively. These amounts were charged to the consolidated statement of operations. The employer contributions vest immediately.

INCOME TAXES (Tables)

12 Months Ended

Oct. 31, 2021

Income Tax Disclosure [Abstract]

SCHEDULE OF INCOME TAX PROVISION (BENEFIT)

The income tax provision (benefit) consists of the following (in thousands):

	October 31, 2021			October 31, 2020
Federal
Current	$	-		$	-
Deferred		141			(4,578	)
State and Local
Current		-			-
Deferred		131			(1,445	)
Foreign
Current		50			50
Deferred		-			-
Change in valuation allowance		(272	)		(6,023	)
Income tax provision (benefit)	$	50		$	50

SCHEDULE OF DEFERRED TAX ASSETS (LIABILITIES)

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands):


	Years Ended
	October 31, 2021			October 31, 2020
Deferred Tax Assets
Net operating loss carryovers	$	32,971		$	28,553
Stock-based compensation		4,566			10,132
Research and development credits		11,371			10,742
Capitalized R&D costs		14,536			13,822
Adoption of ASC 842 – Lease Liability		11			1,691
Other deferred tax assets		92			224
Total deferred tax assets	$	63,547		$	65,164
Valuation allowance		(62,573	)		(62,845	)
Deferred tax asset, net of valuation allowance	$	974		$	2,319

Deferred Tax Liabilities
Adoption of ASC 842 – ROU Asset		(11	)		(1,360	)
Patent cost		(943	)		(917	)
Other deferred tax liabilities		(20	)		(42	)
Total deferred tax liabilities	$	(974	)	$	(2,319	)
Net deferred tax asset (liability)	$	-		$	-

SCHEDULE OF EXPECTED TAX (EXPENSE) BENEFIT BASED ON STATUTORY RATE WITH ACTUAL TAX EXPENSE BENEFIT

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

		2021
	Years Ended
	October 31, 2021			October 31, 2020
US Federal statutory rate		21.00	%		21.00	%
State income tax, net of federal benefit		(0.73	)		5.48
Merger costs		(1.68	)		0.00
Other permanent differences		(0.02	)		(0.05	)
Research and development credits		3.09			1.73
Warrant Liability		1.14			0.00
Foreign taxes		(0.28	)		(0.19	)
Change in valuation allowance		1.52			(22.82	)
Stock option expirations		(24.32	)		(5.33	)
Income tax (provision) benefit		(0.28	)%		(0.19	)%

LICENSING AGREEMENTS

12 Months Ended

Oct. 31, 2021

Business Combination and Asset Acquisition [Abstract]

LICENSING AGREEMENTS

9. LICENSING AGREEMENTS

OS Therapies LLC

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until OST achieves its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis will initiate the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

Provided that OST meets its ongoing obligation to make its Monthly Payments to Advaxis for six consecutive months, Advaxis agrees to transfer, and OST agrees to take full ownership of, the IND application for ADXS31-164 in its entirety to OST, along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development. Until OST makes its Monthly Payments to Advaxis for six consecutive months, Advaxis will continue to bear the costs of the regulatory filing services related to the IND application for ADXS31-164.

Within five business days of achieving the funding milestone of $2,337,500 for the performance of the Children’s Oncology Group study (knowns as the “License Commencement Date”), OST will make a non-refundable and non-creditable payment to Advaxis of $1,550,000 less the cumulative Monthly Payments previously made (the “License Commencement Payment”). Within five days following the License Commencement Date, Advaxis will provide existing drug supply “as is” to OST, and until the drug supply is supplied to OST, Advaxis will bear the storage costs for the drug product. Pursuant to the agreement, the Company is also to receive sales-based milestone payments and royalties on future product sales. In addition, the Company and OST will establish a Joint Steering Committee to oversee the R&D activities.

The promises to (1) Maintain the HER2 product until transfer to OST, (2) Provide the IND application ownership for ADX321-164 to OST, (3) Participate in the Joint Steering Committee, (4) Transfer of IP & licensing rights of ADXS31-164 and related Patents, and (5) Provide Clinical Drug Supply represent one combined performance obligation for revenue recognition purposes. The Company concluded that the transfer of the IP and licensing rights provides OST with a functional, or “right to use,” license, and thus the Company will recognize the upfront fees of $1,550,000 from the license at a point in time. The revenue from the transfer of the license cannot be recognized until the transfer of the corresponding IP to OST has occurred and OST has the ability to benefit from the right to use the license. As the right to use the license begins when OST makes the upfront payment within five days of the License Commencement Date and the IP transfers to OST at that time, the upfront fees from the license will be recognized upon the transfer of the intellectual property to OST.

Since OST is making $25,000 monthly payments that will be creditable against the $1,550,000, as well as additional upfront payments not specified in the contract, the Company will receive payments prior to the performance of the single distinct performance obligation. Due to this, the Company will defer any of the monthly payments until the IP and licensing rights are transferred to OST. However, if OST terminates the contract, which they are able to do with 60-day notice, the Company would recognize any of the payments received when the contract terminates. As of October 31, 2020, OST had made payments totaling $164,653 and this has been recorded as other liabilities in the consolidated balance sheet.

From May 2020 to January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement, and recorded $1,615,000 in revenue. The Company therefore transferred and OST took full ownership of the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

On April 26, 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans and recorded $1,375,000 in revenue. The Company received the amount due from OS Therapies of $1,375,000 in May 2021.

Global BioPharma Inc.

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (GBP), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the years ended October 31, 2021 and 2020, the Company recorded $0.25 million in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.

SCHEDULE OF DEFERRED TAX ASSETS (LIABILITIES) (Details) - USD ($) $ in Thousands	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 32,971	$ 28,553
Stock-based compensation	4,566	10,132
Research and development credits	11,371	10,742
Capitalized R&D costs	14,536	13,822
Adoption of ASC 842 – Lease Liability	11	1,691
Other deferred tax assets	92	224
Total deferred tax assets	63,547	65,164
Valuation allowance	(62,573)	(62,845)
Deferred tax asset, net of valuation allowance	974	2,319
Adoption of ASC 842 – ROU Asset	(11)	(1,360)
Patent cost	(943)	(917)
Other deferred tax liabilities	(20)	(42)
Total deferred tax liabilities	(974)	(2,319)
Net deferred tax asset (liability)

STOCKHOLDERS’ EQUITY

12 Months Ended

Oct. 31, 2021

Equity [Abstract]

STOCKHOLDERS’ EQUITY

6. STOCKHOLDERS’ EQUITY

Lincoln Park Purchase Agreement

On July 30, 2020, the Company entered into a Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Over the 36-month term of the Purchase Agreement, the Company has the right, but not the obligation, from time to time, to sell to Lincoln Park up to an aggregate amount of $20,000,000 of shares of common stock, in its sole discretion and subject to certain conditions, including that the closing price of its common stock is not below $0.10 per share, to direct Lincoln Park to purchase up to 1,000,000 shares (the “Regular Purchase Share Limit”) of its Common Stock (each such purchase, a “Regular Purchase”). Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $1,000,000, unless the parties mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stock to be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustments described in the Purchase Agreement): (i) the lowest sale price for the Company’s common stock on the applicable purchase date, and (ii) the arithmetic average of the three lowest sale prices for the Company’s common stock during the ten trading days prior to the purchase date.

As consideration for entering into the Purchase Agreement, the Company issued 1,084,266 shares of common stock to Lincoln Park as a commitment fee. The shares were valued at approximately $0.6 million and were recorded as deferred offering expenses in the consolidated balance sheet. The deferred charges were charged against paid-in capital upon future proceeds from the sale of common stock under the Lincoln Park Purchase Agreement.

From August 2020 to October 2020, Lincoln Park purchased 11,242,048 shares of common stock for gross proceeds of approximately $5.1 million. Approximately $50,000 of legal fees were netted against the gross proceeds.

Public Offerings

In April 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors. The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 17,577,400 shares (the “Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”), at an offering price of $0.7921 per Share and 7,671,937 pre-funded warrants to certain purchasers whose purchase of additional Shares would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 9.99% of the Company’s outstanding Common Stock immediately following the consummation of the offering (the “Pre-Funded Warrants”). The Shares and Pre-Funded Warrants were sold together with warrants to purchase up to 11,244,135 shares of Common Stock (the “Accompanying Warrants” and together with the Shares and the Pre-Funded Warrants, the “Securities”). The Pre-Funded Warrants were sold for a purchase price of $0.7911 per share and have an exercise price of $0.001 per share. The Pre-Funded Warrants were immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. Each Accompanying Warrant has an exercise price per share of $0.70, became exercisable immediately and will expire on the fifth anniversary of the original issuance date.

The Purchase Agreement also provided for a concurrent private placement (the “Private Placement”) of 14,005,202 warrants to purchase the Company’s Common Stock (the “Private Placement Warrants”) with the purchasers in the Registered Offering. The Private Placement Warrants will be exercisable for an aggregate of 14,005,202 shares of Common Stock at any time on or after such date, if ever, that is 14 days after the Company files an amendment (the “Authorized Shares Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares with the Delaware Secretary of State and on or prior to the date that is five years after such date. The Private Placement Warrants have an exercise price of $0.70 per share.

In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of approximately $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million.

In May 2020, the Company entered into a sales agreement related to an ATM equity offering program pursuant to which the Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./Alliance Global Partners, as sales agent. From May 2020 to October 2020, the Company sold 2,489,104 shares of its common stock under the ATM program for $1.583 million, or an average of $0.64 per share, and received net proceeds of $1.531 million, net of commissions of $52,000. In March 2021, the Company sold 886,048 shares of its common stock under the ATM program for $762,000, or an average of $0.86 per share, and received net proceeds of $737,000, net of commissions of $25,000.

In January 2020, the Company closed on a public offering of 10,000,000 shares of its common stock at a public offering price of $1.05, for gross proceeds of $10.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 5,000,000 shares of common stock. The warrants have an exercise price per share of $1.25, are exercisable during the period beginning on the six-month anniversary of the date of its issuance (the “Initial Exercise Date”) and will expire on the fifth anniversary of the Initial Exercise Date. The warrants contain a change of control provision whereby if the change of control is within the Company’s control, the warrants could be settled in cash based on the Black-Scholes value of the warrants at the option of the warrant holder. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $9.6 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)	Oct. 31, 2021	Oct. 31, 2020
Leases
Weighted-average remaining lease term	1 year 4 months 24 days	5 years 1 month 6 days
Weighted-average discount rate	3.79%	6.50%

INTANGIBLE ASSETS (Tables)

12 Months Ended

Oct. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

SUMMARY OF INTANGIBLE ASSETS

Intangible assets consist of the following (in thousands):

SUMMARY OF INTANGIBLE ASSETS

	2021			2020
	October 31,
	2021			2020
Patents	$	4,836		$	4,479
License		777			777
Software		98			117
Total intangibles		5,711			5,373
Accumulated amortization		(2,357	)		(2,112	)
Net intangible assets	$	3,354		$	3,261

SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS

At October 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

		1
2022	$	277
2023		277
2024		277
2025		277
2026		277
Thereafter		1,969
Total	$	3,354

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

12 Months Ended

Oct. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;

	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and

	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

Termination of Merger Agreement; Strategic Considerations

On July 4, 2021, the Company entered into a Merger Agreement (the “Merger Agreement”), subject to shareholder approval, with Biosight Ltd. (“Biosight”) and Advaxis Ltd. (“Merger Sub”), a direct, wholly-owned subsidiary of Advaxis. Under the terms of the agreement, Biosight was to merge with and into Merger Sub, with Biosight continuing as the surviving company and a wholly-owned subsidiary of Advaxis (the “Merger”). Immediately after the merger, Advaxis stockholders as of immediately prior to the merger were expected to own approximately 25% of the outstanding shares of the combined company and former Biosight shareholders were expected to own approximately 75% of the outstanding shares of the combined company.

On December 30, 2021, the Company terminated the Merger Agreement, as the Company was unable to obtain shareholder approval to complete the transaction. As announced in December 2021, the Company plans to continue to explore additional options to maximize stockholder value.

Liquidity and Management’s Plans

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

As of October 31, 2021, the Company had approximately $41.6 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors. Over the past year, the Company has taken steps to obtain additional financing, including conducting sales of its common stock through its at-the-market (“ATM”) program through A.G.P./Alliance Global Partners, the completion of a public offering in November 2020 and the completion of a registered direct offering and concurrent private placement with two healthcare-focused, institutional investors in April 2021, as further described below. The Company also received aggregate proceeds of approximately $3.8 million during the year ended October 31, 2021 upon the exercise of outstanding warrants, which were payable upon exercise.

In April 2021, the Company entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock, (ii) 7,671,937 pre-funded warrants to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock (“Accompanying Warrants”) in a registered direct offering (the “April 2021 Registered Direct Offering”). The Company also issued to the investors, in a concurrent private placement (the “April 2021 Private Placement” and together with the April 2021 Registered Direct Offering, the “April 2021 Offering”), unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock (the “Private Placement Warrants”). The Company received gross proceeds of approximately $20 million, before deducting the fees and expenses payable by the Company in connection with the April 2021 Offering.

On November 27, 2020, the Company completed an underwritten public offering of 26,666,666 shares of common stock and common stock warrants to purchase up to 13,333,333 shares of common stock (the “November 2020 Offering”). On November 24, 2020, the underwriters notified the Company that they had exercised their option to purchase an additional 3,999,999 shares of common stock and 1,999,999 warrants in full. The Company received gross proceeds of approximately $9.2 million, before deducting the fees and expenses payable by the Company in connection with the November 2020 Offering.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

LEASES

12 Months Ended

Oct. 31, 2021

Leases

LEASES

11. LEASES

Operating Leases

The Company leased its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. The Company had the option to renew the lease term for two additional five-year terms. The renewal periods were not included the lease term for purposes of determining the lease liability or right-of-use asset. The Company provided a security deposit of approximately $182,000, which was recorded as other assets in the consolidated balance sheet as of October 31, 2020.

The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:

	●	As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease.

	●	Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.

	●	Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.

	●	Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability.

On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4.5 million and lease liability of approximately $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $0.1 million.

On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one-year term upon six months written notice to the landlord. This new lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeds one-year, the lease no longer qualifies for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

Supplemental balance sheet information related to leases as of October 31 was as follows (in thousands):

	October 31, 2021		October 31, 2020
Operating leases:
Operating lease right-of-use assets	$	40	$	4,839

Operating lease liability	$	28	$	962
Operating lease liability, net of current portion		12		5,055
Total operating lease liabilities	$	40	$	6,017

Supplemental lease expense related to leases was as follows (in thousands):

SCHEDULE OF LEASE EXPENSES

Lease Cost (in thousands)	Statements of Operations Classification	For the Fiscal Year Ended October 31, 2021		For the Fiscal Year Ended October 31, 2020
Operating lease cost	General and administrative	$	1,302	$	1,158
Short-term lease cost	General and administrative		14		320
Variable lease cost	General and administrative		180		547
Total lease expense		$	1,496	$	2,025

Other information related to leases where the Company is the lessee is as follows:

	October 31, 2021			October 31, 2020
Weighted-average remaining lease term		1.4 years			5.1 years
Weighted-average discount rate		3.79	%		6.5	%

Supplemental cash flow information related to operating leases was as follows:

	For the Fiscal Year Ended October 31, 2021		For the Fiscal Year Ended October 31, 2020
Cash paid for operating lease liabilities	$	547	$	1,233

Future minimum lease payments under non-cancellable leases as of October 31, 2021 were as follows:

Fiscal Year ending October 31,
2022	$	29
2023		12
Total minimum lease payments		41
Less: Imputed interest		(1	)
Total	$	40

SUMMARY OF ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Oct. 31, 2021	Oct. 31, 2020
Payables and Accruals [Abstract]
Salaries and other compensation	$ 55	$ 737
Vendors	2,168	671
Professional fees	613	329
Total accrued expenses	$ 2,836	$ 1,737

SUBSEQUENT EVENTS

12 Months Ended

Oct. 31, 2021

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

15. SUBSEQUENT EVENTS

On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. The shares of Series D preferred stock are convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share. The conversion, at the option of the stockholder, may occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock will also have a liquidation preference over the common stock, and may be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. The Company and the holders of the Series D preferred stock will also enter into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series D preferred stock. Total gross proceeds from the offering, before deducting the financial advisor’s fees and other estimated offering expenses, are $4.75 million.

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

12 Months Ended

Oct. 31, 2021

Common Stock Purchase Warrants And Warrant Liability

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of October 31, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 shares of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:

SCHEDULE OF OUTSTANDING WARRANTS

Exercise Price			Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	281.25			25	N/A	Other Warrants
$	2.80	*		327,338	July 2024	July 2019 Public Offering
$	0.30			70,297	September 2024	September 2018 Public Offering
$	0.35			4,578,400	November 2025	November 2020 Public Offering
$	0.70			11,244,135	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	0.70			14,005,202	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants
	Grand Total			30,225,997

*	During the year ended October 31, 2021, the cashless exercise provision of these warrants expired and the exercise price adjusted to $2.80.

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	281.25		25	N/A	Other Warrants
$	-		327,338	July 2024	July 2019 Public Offering
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

A summary of warrant activity was as follows (In thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2019		432,142		$	0.08		4.76	$	114,069
Issued		5,000,000			1.25		-
Exercised *		(33,916	)		0.02
Exchanged		(5,000,000	)		1.25
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		48,254,606			0.48		-
Exercised		(18,427,435	)		0.20
Outstanding and exercisable warrants at October 31, 2021		30,225,397		$	0.67		4.63	$	631,089

*	Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.

As of October 31, 2021, the Company had 16,149,898 of its total 30,225,397 outstanding warrants classified as equity (equity warrants). At October 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders equity section of the consolidated balance sheets.

Shares Issued for Warrants Exercises

During the year ended October 31, 2021, warrant holders from the Company’s November 2020 offering exercised 10,754,932 warrants in exchange for 10,754,932 shares of the Company’s common stock and warrant holders from the Company’s April 2021 Offering exercised 7,671,937 pre-funded warrants in exchange for 7,671,937 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of approximately $3.8 million which were payable upon exercise.

Shares Issued in Settlement of Equity Warrants

On October 16, 2020, the Company entered into private exchange agreements with certain holders of warrants issued in connection with the Company’s January 2020 public offering of common stock and warrants. The warrants being exchanged provide for the purchase of up to an aggregate of 5,000,000 shares of our common stock at an exercise price of $1.25 per share. The warrants became exercisable on July 21, 2020 and have an expiration date of July 21, 2025. Pursuant to such exchange agreements, the Company agreed to issue 3,000,000 shares of common stock to the investors in exchange for the warrants. The fair value of these warrants approximated the fair value of shares issued in the exchange for these warrants. The Company used the closing stock price to value the shares and Black Scholes model to value these warrants on the date of the exchange. In determining the fair warrant of the warrants issued on October 16, 2020, the Company used the following inputs in its Black-Sholes model: exercise price $1.25, stock price $0.406, expected term 4.76 years, volatility 101.18% and risk-free interest rate 0.32%. In connection with the exchange of warrants for common stock, the Company recorded a loss of approximately $77,000 as the fair value of the shares issued exceeded the fair value of warrants exchanged.

Warrant Liability

As of October 31, 2021, the Company had 14,075,499 of its total 30,225,397 outstanding warrants from April 2021 Private Placement Offering and September 2018 Public Offering classified as liabilities (liability warrants). At October 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants from the September 2018 Public Offering classified as liabilities (liability warrants).

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of October 31, 2021, the Company does not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting held on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

	October 31, 2021			April 14, 2021
Exercise Price	$	0.70		$	0.70
Stock Price	$	0.485		$	0.57
Expected Term		5.00 years			5.00 years
Volatility %		106	%		106	%
Risk Free Rate		1.18	%		0.85	%

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of October 31, 2021, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.30. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability for the September 2018 Public Offering warrants at October 31, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	October 31, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.485		$	0.34
Expected Term		2.87 years			3.87 years
Volatility %		123	%		106	%
Risk Free Rate		0.77	%		0.29	%

At October 31, 2021 and October 31, 2020, the fair value of the warrant liability was approximately $4.9 million and $17,000, respectively. For the years ended October 31, 2021 and 2020, the Company reported income of approximately $1.0 million and $0, respectively, due to changes in the fair value of the warrant liability.

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)					1 Months Ended						3 Months Ended	6 Months Ended	12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Jul. 30, 2021	Apr. 30, 2021	Nov. 27, 2020	Nov. 24, 2020	May 31, 2021	Apr. 30, 2021	Mar. 31, 2021	Nov. 30, 2020	May 31, 2020	Jan. 31, 2020	Oct. 31, 2020	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020	Jun. 03, 2021	Jun. 01, 2021	Apr. 14, 2021
Subsidiary, Sale of Stock [Line Items]
Common stock, authorized											170,000,000	170,000,000	170,000,000	170,000,000	300,000,000	170,000,000
Number of warrants to purchase common stock											398,226	398,226	30,225,997	398,226
Stock Issued During Period, Value, New Issues													$ 22,233,000	$ 11,066,000
Number of common stock purchased											11,242,048
Gross proceeds from common stock											$ 5,100,000		$ 28,115,000	$ 15,496,000
Proceeds from netted legal fees											$ 50,000
Common stock, par value											$ 0.001	$ 0.001	$ 0.001	$ 0.001
Warrants exercise price											0.372	$ 0.372	$ 0.30	0.372
Proceeds from sale of common shares							$ 886,048,000					$ 2,489,104,000
Warrants exercise price							$ 0.86		$ 0.64
Net proceeds from offering							$ 762,000	$ 8,500,000	$ 40,000,000	$ 9,600,000		$ 1,583,000
ATM Program [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds from offering					$ 1,531,000		737,000
Proceeds from commission							$ 25,000		$ 52,000
Pre Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price		$ 0.70				$ 0.70
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, authorized													300,000,000
Share price per share								$ 0.30		$ 1.05
Stock Issued During Period, Shares, New Issues			26,666,666
Number of common stock shares sold								30,666,665		10,000,000
Proceeds from sale of common shares										$ 10,500,000
Net proceeds from offering													$ 3,800,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock								15,333,332
Warrants exercise price													$ 0.70
Warrants exercise price								$ 0.35		$ 1.25
Warrants and Rights Outstanding, Term								5 years									5 years
November 2020 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock			13,333,333
Proceeds from sale of common shares				$ 9,200,000
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price											281.25	$ 281.25		281.25
Maximum [Member] \| Amended and Restated Certificate of Incorporation [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, authorized		300,000,000				300,000,000
Maximum [Member] \| Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock										5,000,000
Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price											$ 0	$ 0		$ 0
Minimum [Member] \| Amended and Restated Certificate of Incorporation [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, authorized		170,000,000				170,000,000
Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Agreement description	Over the 36-month term of the Purchase Agreement, the Company has the right, but not the obligation, from time to time, to sell to Lincoln Park up to an aggregate amount of $20,000,000 of shares of common stock, in its sole discretion and subject to certain conditions, including that the closing price of its common stock is not below $0.10 per share, to direct Lincoln Park to purchase up to 1,000,000 shares (the “Regular Purchase Share Limit”) of its Common Stock (each such purchase, a “Regular Purchase”). Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $1,000,000, unless the parties mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stock to be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustments described in the Purchase Agreement): (i) the lowest sale price for the Company’s common stock on the applicable purchase date, and (ii) the arithmetic average of the three lowest sale prices for the Company’s common stock during the ten trading days prior to the purchase date.
Common stock, authorized	20,000,000
Share price per share	$ 0.10
Stock Issued During Period, Shares, New Issues	1,084,266
Stock Issued During Period, Value, New Issues	$ 600,000
Purchase Agreement [Member] \| Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock		14,005,202				14,005,202
Warrants exercise price		$ 0.70				$ 0.70
Purchase Agreement [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock	1,000,000
Securities Purchase Agreements [Member] \| Pre Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Share price per share		0.7911				0.7911
Common stock, par value		0.001				0.001
Securities Purchase Agreements [Member] \| IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Share price per share		0.7921				$ 0.7921
Number of common stock shares sold						17,577,400
Common stock, par value		$ 0.001				$ 0.001
Pre-funded warrants to purchase common shares		7,671,937				7,671,937
Ownership percentage		9.99%				9.99%
Securities Purchase Agreements [Member] \| Maximum [Member] \| IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock		11,244,135				11,244,135
Definitive Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock		11,244,135				11,244,135
Definitive Agreements [Member] \| April 2021 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase common stock		14,005,202				14,005,202
Proceeds from sale of common shares		$ 20,000,000

ACCRUED EXPENSES

12 Months Ended

Oct. 31, 2021

Payables and Accruals [Abstract]

ACCRUED EXPENSES

5. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses (in thousands):

SUMMARY OF ACCRUED EXPENSES

	2021		2020
	October 31,
	2021		2020
Salaries and other compensation	$	55	$	737
Vendors		2,168		671
Professional fees		613		329
Total accrued expenses	$	2,836	$	1,737

SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance	1,011,768	560,490
Weighted Average Exercise Price, Outstanding, Beginning	$ 33.43	$ 71.56
Weighted Average Remaining Contractual Life In Years, Outstanding, Beginning	8 years 14 days	7 years 4 months 2 days
Aggregate Intrinsic Value, Beginning	$ 4	$ 1
Shares, Granted	50,000	645,000
Weighted Average Exercise Price, Granted	$ 0.39	$ 0.61
Shares, Cancelled or Expired	(167,489)	(193,722)
Weighted Average Exercise Price, Cancelled or Expired	$ 98.93	$ 34.47
Shares, Exercised	(333)
Weighted average exercise price, Exercised	$ 0.30
Shares, Outstanding, Ending Balance	893,946	1,011,768
Weighted Average Exercise Price, Outstanding, Ending	$ 19.32	$ 33.43
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending balance	7 years 9 months 18 days
Aggregate Intrinsic Value, Ending	$ 27	$ 4
Shares, Vested and Exercisable	456,506
Weighted Average Exercise Price, Vested and Exercisable	$ 37.03
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	6 years 11 months 23 days
Aggregate Intrinsic Value, Vested and Exercisable	$ 15

INTANGIBLE ASSETS

12 Months Ended

Oct. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

4. INTANGIBLE ASSETS

Intangible assets consist of the following (in thousands):

SUMMARY OF INTANGIBLE ASSETS

	2021			2020
	October 31,
	2021			2020
Patents	$	4,836		$	4,479
License		777			777
Software		98			117
Total intangibles		5,711			5,373
Accumulated amortization		(2,357	)		(2,112	)
Net intangible assets	$	3,354		$	3,261

The expirations of the existing patents range from 2021 to 2039 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of approximately $0.1 million and $1.7 million were abandoned and were charged to general and administrative expenses in the consolidated statement of operations for the years ended October 31, 2021 and 2020, respectively. Intangible asset amortization expense that was charged to general and administrative expense in the consolidated statement of operations was approximately $0.3 million for each of the years ended October 31, 2021 and 2020, respectively.

Management has reviewed its intangible assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the consolidated balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and other products that are in development or out-licensed. However, if a competitor were to gain FDA approval for a treatment before the Company or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding our studies and developing its intellectual property, the Company would likely record an impairment to certain of these assets.

At October 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

		1
2022	$	277
2023		277
2024		277
2025		277
2026		277
Thereafter		1,969
Total	$	3,354

CONTINGENCIES (Details Narrative) - Especificos Stendhal SA de CV [Member] $ in Millions	Sep. 19, 2019 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Damages sought value by plaintiff	$ 3.0
Litigation expense	0.3
Due from related party	$ 3.0

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

+ Details

SUMMARY OF RSU ACTIVITY AND RELATED INFORMATION (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of RSUs, Unvested Beginning Balance	5,556	14,706
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance	$ 24.32	$ 47.62
Number of RSUs, Vested	(5,555)	(8,870)
Weighted-Average Grant Date Fair Value, Vested	$ 24.30	$ 60.59
Number of RSUs, Cancelled	(1)	(280)
Weighted-Average Grant Date Fair Value, Cancelled	$ 125.25	$ 98.80
Number of RSUs, Unvested Ending Balance		5,556
Weighted-Average Grant Date Fair Value, Unvested Ending Balance		$ 24.32

LICENSING AGREEMENTS (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Apr. 26, 2021	Sep. 04, 2019	Sep. 04, 2018	May 31, 2021	Apr. 30, 2021	Jan. 31, 2021	Oct. 31, 2021	Oct. 31, 2020
Contract with Customer, Liability								$ 165,000
Global BioPharma, Inc [Member] \| License and Service [Member]
Revenue							250,000	$ 250,000
OS Therapies [Member]
Contract with Customer, Liability							$ 164,653
OS Therapies [Member] \| Within Five Business Days [Member]
Funding milestone payment		$ 2,337,500
Non-refundable and non-creditable payment		1,550,000
OS Therapies [Member] \| Creditable [Member]
Non-refundable and non-creditable payment		$ 1,550,000
Development, License and Supply Agreement [Member] \| OS Therapies [Member]
Revenue	$ 1,375,000				$ 25,000
Funding milestone payment			$ 2,337,500		$ 1,550,000	$ 1,615,000
Upfront payment						$ 1,615,000
Funding for milestone payment				$ 1,375,000

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forward	$ 314,800,000	$ 299,200,000
Net operating loss and deferred tax asset does not include nol's	$ 56,000,000.0
Operating loss expiration year	2038
New jersey state net operating loss carryovers	$ 153,700,000	137,600,000
Interest or penalties on unpaid tax	$ 0	$ 0
GPP Revenue [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Description	a Taiwan Excise tax of $50,000 levied in connection with the GBP Revenue.

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Thousands				1 Months Ended		6 Months Ended	12 Months Ended
	Apr. 30, 2021	Nov. 27, 2020	Nov. 24, 2020	Mar. 31, 2021	Jan. 31, 2020	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020	Jul. 04, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and Cash Equivalents, at Carrying Value						$ 25,178	$ 41,614	$ 25,178
Proceeds from warrant exercises							$ 3,771
Number of warrants to purchase common stock						398,226	30,225,997	398,226
Proceeds from sale of common shares				$ 886,048		$ 2,489,104
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							333
IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued		26,666,666
Proceeds from sale of common shares					$ 10,500
November 2020 Offering [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants to purchase common stock		13,333,333
Proceeds from sale of common shares			$ 9,200
Underwriters [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			3,999,999
Warrant exercises shares			1,999,999
Merger Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of outstanding shares									75.00%
Definitive Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants to purchase common stock	11,244,135
Definitive Agreements [Member] \| April 2021 Offering [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants to purchase common stock	14,005,202
Proceeds from sale of common shares	$ 20,000
Definitive Agreements [Member] \| Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued	17,577,400
Pre-funded warrants to purchase common shares	7,671,937
Number of warrants to purchase common stock	7,671,937

SUMMARY OF FAIR VALUE OF STOCK OPTIONS GRANTED OF BSM (Details)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years
Expected volatility	103.27%
Expected dividends	0.00%	0.00%
Risk free interest rate	0.53%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		5 years 6 months
Expected volatility		100.27%
Risk free interest rate		0.36%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		6 years 6 months
Expected volatility		105.21%
Risk free interest rate		0.62%

SUBSEQUENT EVENTS (Details Narrative)	1 Months Ended		12 Months Ended
SUBSEQUENT EVENTS (Details Narrative)	Jan. 31, 2022 $ / shares shares	Jan. 31, 2022 USD ($) $ / shares	Oct. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)	Mar. 31, 2021 $ / shares	Nov. 30, 2020 $ / shares	May 31, 2020 $ / shares	Jan. 31, 2020 $ / shares
Subsequent Event [Line Items]
Stated value \| $			$ 22,233,000	$ 11,066,000
Share purchase price					$ 0.86		$ 0.64
Series D Preferred Stock [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Preferred stock conversion price	$ 0.25	$ 0.25
Liquidation preference	The Series D preferred stock will also have a liquidation preference over the common stock, and may be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value
Private Placement [Member]
Subsequent Event [Line Items]
Share purchase price						$ 0.35		$ 1.25
Private Placement [Member] \| Series D Preferred Stock [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Gross proceeds from offering \| $		$ 4,750,000
Private Placement [Member] \| Institutional Investors [Member] \| Series D Preferred Stock [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Advaxis public offerings, net of offering costs, shares \| shares	1,000,000
Stated value \| $		$ 5,000,000
Share purchase price	$ 4.75	$ 4.75
Issue discount	0.05

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2021	Oct. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	145,638,459	78,074,023
Common stock, shares outstanding	145,638,459	78,074,023

SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Current
Deferred	141	(4,578)
Current
Deferred	131	(1,445)
Current	50	50
Deferred
Change in valuation allowance	(272)	(6,023)
Income tax provision (benefit)	$ 50	$ 50

SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Oct. 31, 2021	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 277
2023	277
2024	277
2025	277
2026	277
Thereafter	1,969
Net intangible assets	$ 3,354	$ 3,261

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Oct. 31, 2021

Accounting Policies [Abstract]

Estimates

Estimates

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Revenue Recognition

Revenue Recognition

Collaborative Arrangements

Collaborative Arrangements

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentration of Credit Risk

Concentration of Credit Risk

Deferred Expenses

Deferred Expenses

Property and Equipment

Property and Equipment

When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible Assets

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

	●	the asset’s ability to continue to generate income from operations and positive cash flow in future periods;
	●	loss of legal ownership or title to the asset(s);
	●	significant changes in the Company’s strategic business objectives and utilization of the asset(s); and
	●	the impact of significant negative industry or economic trends.

Leases

Leases

Net Income (Loss) per Share

Net Income (Loss) per Share

	As of October 31,
	2021		2020
Warrants		30,225,397		398,226
Stock options		893,946		1,011,768
Restricted stock units		-		5,556
Total		31,119,343		1,415,550

Research and Development Expenses

Research and Development Expenses

Stock Based Compensation

Stock Based Compensation

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying value of financial instruments, including cash and cash equivalents and accounts payable, approximated fair value as of the balance sheet date presented, due to their short maturities.

Derivative Financial Instruments

Derivative Financial Instruments

Sequencing Policy

Sequencing Policy

Income Taxes

Income Taxes

Recent Accounting Standards

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

FAIR VALUE (Tables)

12 Months Ended

Oct. 31, 2021

Fair Value Disclosures [Abstract]

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2021 and October 31, 2020:

October 31, 2021	Level 1		Level 2		Level 3		Total
Cash equivalents (money market funds)	$	17,153	$	-	$	-	$	17,153
Common stock warrant liability, warrants exercisable at $0.30 through September 2024		-		-		27		27
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		4,902		4,902
Total	$	17,153	$	-	$	4,929	$	22,082

October 31, 2020	Level 1		Level 2		Level 3		Total
Cash equivalents (money market funds)	$	17,149	$	-	$	-	$	17,149
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-		17		17
Total	$	17,149	$		$	17	$	17,166

SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANT LIABILITIES

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:


	Year Ended October 31,
	2021			2020
Beginning balance	$	17		$	19
Warrants issued		5,882			-
Warrant exercises		-			(2	)
Change in fair value		(970	)		-
Ending balance	$	4,929		$	17

SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Oct. 31, 2021	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,836	$ 4,479
License	777	777
Software	98	117
Total intangibles	5,711	5,373
Accumulated amortization	(2,357)	(2,112)
Net intangible assets	$ 3,354	$ 3,261

SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Offsetting Assets [Line Items]
Options Outstanding, Intrinsic Value	$ 27	$ 4	$ 1
Options Exercisable, Intrinsic Value	$ 15
Exercise Price Range One [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	$ 0.30
Exercise Price Range, upper limit	$ 10.00
Number Outstanding, Options Outstanding	727,879
Weighted Average Remaining Contractual, Options Outstanding	8 years 5 months 4 days
Weighted Average Exercise Price, Options Outstanding	$ 1.06
Options Outstanding, Intrinsic Value	$ 27
Number Outstanding, Options Exercisable	290,439
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	8 years 2 months 23 days
Weighted Average Exercise Price, Options Exercisable	$ 1.40
Options Exercisable, Intrinsic Value	$ 15
Exercise Price Range Two [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	$ 10.01
Exercise Price Range, upper limit	$ 100.00
Number Outstanding, Options Outstanding	90,432
Weighted Average Remaining Contractual, Options Outstanding	6 years 2 months 19 days
Weighted Average Exercise Price, Options Outstanding	$ 29.02
Number Outstanding, Options Exercisable	90,432
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	6 years 2 months 19 days
Weighted Average Exercise Price, Options Exercisable	$ 29.02
Exercise Price Range Three [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	100.01
Exercise Price Range, upper limit	$ 200.00
Number Outstanding, Options Outstanding	50,938
Weighted Average Remaining Contractual, Options Outstanding	3 years 5 months 19 days
Weighted Average Exercise Price, Options Outstanding	$ 162.17
Number Outstanding, Options Exercisable	50,938
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	3 years 5 months 19 days
Weighted Average Exercise Price, Options Exercisable	$ 162.17
Exercise Price Range Four [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	200.01
Exercise Price Range, upper limit	$ 277.5
Number Outstanding, Options Outstanding	24,697
Weighted Average Remaining Contractual, Options Outstanding	2 years 2 months 19 days
Weighted Average Exercise Price, Options Outstanding	$ 227.35
Number Outstanding, Options Exercisable	24,697
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	2 years 2 months 19 days
Weighted Average Exercise Price, Options Exercisable	$ 227.35

FAIR VALUE

12 Months Ended

Oct. 31, 2021

Fair Value Disclosures [Abstract]

FAIR VALUE

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2021 and October 31, 2020:

October 31, 2021	Level 1		Level 2		Level 3		Total
Cash equivalents (money market funds)	$	17,153	$	-	$	-	$	17,153
Common stock warrant liability, warrants exercisable at $0.30 through September 2024		-		-		27		27
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		4,902		4,902
Total	$	17,153	$	-	$	4,929	$	22,082

October 31, 2020	Level 1		Level 2		Level 3		Total
Cash equivalents (money market funds)	$	17,149	$	-	$	-	$	17,149
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-		17		17
Total	$	17,149	$		$	17	$	17,166

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:


	Year Ended October 31,
	2021			2020
Beginning balance	$	17		$	19
Warrants issued		5,882			-
Warrant exercises		-			(2	)
Change in fair value		(970	)		-
Ending balance	$	4,929		$	17

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Oct. 31, 2019	$ 50	$ 423,750	$ (384,269)	$ 39,531
Balance, shares at Oct. 31, 2019	50,201,671
Stock-based compensation		891		891
Stock-based compensation, shares	8,870
Tax withholdings paid on equity awards		(1)		(1)
Tax shares sold to pay for tax withholdings on equity awards		1		1
Issuance of shares to employees under ESPP Plan		7		7
Issuance of shares to employees under ESPP Plan, shares	14,148
ESPP Expense		1		1
Warrant exercises		2		2
Warrant exercises, shares	33,916
Shares issued in settlement of warrants	$ 3	74		77
Shares issued in settlement of warrants, shares	3,000,000
Advaxis public offerings, net of offering costs	$ 13	11,053		11,066
Advaxis public offerings, net of offering costs, shares	12,489,104
Commitment fee shares issued for equity line	$ 1	643		644
Commitment fee shares issued for equity line, shares	1,084,266
Shares issued under equity line	$ 11	4,419		4,430
Shares issued under equity line, shares	11,242,048
Net Loss			(26,469)	(26,469)
Ending balance, value at Oct. 31, 2020	$ 78	440,840	(410,738)	30,180
Balance, shares at Oct. 31, 2020	78,074,023
Stock-based compensation		566		566
Stock-based compensation, shares	5,555
Stock option exercises
Stock option exercises, shares	333			333
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares	1,000
Warrant exercises	$ 18	3,753		3,771
Warrant exercises, shares	18,427,435
Advaxis public offerings, net of offering costs	$ 50	22,183		22,233
Advaxis public offerings, net of offering costs, shares	49,130,113
Net Loss			(17,862)	(17,862)
Ending balance, value at Oct. 31, 2021	$ 146	$ 467,342	$ (428,600)	$ 38,888
Balance, shares at Oct. 31, 2021	145,638,459

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024	$ 4,929	$ 17	$ 19
Warrant exercise price per share	$ 0.30	$ 0.372
Total	$ 22,082	$ 17,166
Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024	$ 4,902
Warrant exercise price per share	$ 0.70
Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024	$ 27	17
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)	17,153	17,149
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	17,153	17,149
Fair Value, Inputs, Level 1 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024
Fair Value, Inputs, Level 1 [Member] \| Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)	17,153	17,149
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 2 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024
Fair Value, Inputs, Level 2 [Member] \| Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	4,929	17
Fair Value, Inputs, Level 3 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024	4,902
Fair Value, Inputs, Level 3 [Member] \| Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $0.372 through September 2024	27	17
Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)